BRPI1007934A2 - "dabigatrana liofilizada" - Google Patents
"dabigatrana liofilizada"Info
- Publication number
- BRPI1007934A2 BRPI1007934A2 BRPI1007934A BRPI1007934A BRPI1007934A2 BR PI1007934 A2 BRPI1007934 A2 BR PI1007934A2 BR PI1007934 A BRPI1007934 A BR PI1007934A BR PI1007934 A BRPI1007934 A BR PI1007934A BR PI1007934 A2 BRPI1007934 A2 BR PI1007934A2
- Authority
- BR
- Brazil
- Prior art keywords
- lyophilized dabigatran
- dabigatran
- lyophilized
- Prior art date
Links
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 title 1
- 229960003850 dabigatran Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2430/00—Assays, e.g. immunoassays or enzyme assays, involving synthetic organic compounds as analytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/45—Reference solutions for assays of biological material containing protease inhibitors, e.g. sulfonylfluorides, chloromethylketones or organophosphates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09151865.4 | 2009-02-02 | ||
| EP09151865 | 2009-02-02 | ||
| PCT/EP2010/050925 WO2010086329A1 (en) | 2009-02-02 | 2010-01-27 | Lyophilised dabigatran |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1007934A2 true BRPI1007934A2 (pt) | 2016-02-23 |
| BRPI1007934B1 BRPI1007934B1 (pt) | 2021-08-31 |
Family
ID=40791651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1007934-3A BRPI1007934B1 (pt) | 2009-02-02 | 2010-01-27 | Composição de dabigatrana liofilizada, seu processo de fabricação, uso, ensaio e kit |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9063163B2 (pt) |
| EP (1) | EP2391893B1 (pt) |
| JP (1) | JP5611983B2 (pt) |
| KR (1) | KR101822368B1 (pt) |
| CN (1) | CN102292641A (pt) |
| AU (1) | AU2010209804B2 (pt) |
| BR (1) | BRPI1007934B1 (pt) |
| CA (1) | CA2750976C (pt) |
| DK (1) | DK2391893T3 (pt) |
| EA (1) | EA020194B1 (pt) |
| ES (1) | ES2525251T3 (pt) |
| IL (1) | IL213573A (pt) |
| MX (1) | MX2011007301A (pt) |
| NZ (1) | NZ593787A (pt) |
| PL (1) | PL2391893T3 (pt) |
| WO (1) | WO2010086329A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0907598A2 (pt) * | 2008-03-28 | 2015-07-21 | Boehringer Ingelheim Int | Processo para o preparo de formulações de dabigatrana administradas por via oral |
| US20110123635A1 (en) | 2008-07-14 | 2011-05-26 | Boehringer Ingelheim International Gmbh | Method for manufacturing medicinal compounds containing dabigatran |
| CN103356614A (zh) | 2008-11-11 | 2013-10-23 | 贝林格尔.英格海姆国际有限公司 | 使用达比加群酯或其盐治疗或预防血栓形成且与常规华法林疗法相比具有改良安全性的方法 |
| EA201201202A1 (ru) * | 2010-03-01 | 2013-04-30 | Рациофарм Гмбх | Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана |
| US20130345262A1 (en) | 2012-06-25 | 2013-12-26 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
| CN102793699B (zh) * | 2012-08-06 | 2014-06-04 | 严轶东 | 一种含有达比加群酯的药用组合物 |
| US9176154B2 (en) * | 2012-12-12 | 2015-11-03 | Bio-Rad Laboratories, Inc. | Calibration process and system |
| JP6278454B2 (ja) * | 2013-03-29 | 2018-02-14 | 株式会社Ｌｓｉメディエンス | 生体試料中の直接トロンビン阻害薬の測定試薬及び測定方法 |
| JP7110360B2 (ja) | 2017-10-09 | 2022-08-01 | テルモ ビーシーティー バイオテクノロジーズ，エルエルシー | 凍結乾燥方法 |
| JP7471316B2 (ja) | 2019-03-14 | 2024-04-19 | テルモ ビーシーティー バイオテクノロジーズ，エルエルシー | マルチパート凍結乾燥容器 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| US5858289A (en) * | 1997-02-24 | 1999-01-12 | Global Consulting, Inc. | Process for preparing compressed shape of ceramic fiber |
| US6414008B1 (en) | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
| WO2001007921A2 (en) | 1999-07-23 | 2001-02-01 | Medical Analysis Systems, Inc. | Stabilized coagulation control reagent |
| CN1234363C (zh) * | 2003-04-15 | 2006-01-04 | 上海医药工业研究院 | 含有右雷佐生的冻干组合物及其制备方法 |
| US7148067B2 (en) | 2004-08-31 | 2006-12-12 | The Board Of Trustees Of The University Of Illinois | Thromboplastin reagents |
| DE102005020002A1 (de) * | 2005-04-27 | 2006-11-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester |
| DE102005028018A1 (de) * | 2005-06-16 | 2006-12-21 | Dade Behring Marburg Gmbh | Verfahren zur Standardisierung von Gerinnungstesten |
| CN1786023A (zh) * | 2005-07-27 | 2006-06-14 | 西安绿谷制药有限公司 | 灵芝多糖肽标准品及其制备方法与应用 |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| EP2043632A2 (en) * | 2006-07-17 | 2009-04-08 | Boehringer Ingelheim International GmbH | New indications for direct thrombin inhibitors |
| CN101489549A (zh) * | 2006-07-17 | 2009-07-22 | 贝林格尔.英格海姆国际有限公司 | 直接凝血酶抑制剂在心血管领域的新的适应症 |
| CN101313912A (zh) * | 2007-05-31 | 2008-12-03 | 复旦大学附属中山医院 | 松果菊苷在制备治疗帕金森病的药物中的应用 |
| CN101105498B (zh) * | 2007-08-08 | 2011-06-01 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | 人、大鼠、小鼠hsp70双抗夹心法检测试剂盒 |
| CN101135688A (zh) * | 2007-09-27 | 2008-03-05 | 宁波美康生物科技有限公司 | 血清中果糖胺nbt测定方法 |
-
2010
- 2010-01-27 PL PL10701670T patent/PL2391893T3/pl unknown
- 2010-01-27 DK DK10701670.1T patent/DK2391893T3/da active
- 2010-01-27 AU AU2010209804A patent/AU2010209804B2/en active Active
- 2010-01-27 EA EA201101152A patent/EA020194B1/ru not_active IP Right Cessation
- 2010-01-27 BR BRPI1007934-3A patent/BRPI1007934B1/pt active IP Right Grant
- 2010-01-27 JP JP2011546830A patent/JP5611983B2/ja active Active
- 2010-01-27 KR KR1020117017988A patent/KR101822368B1/ko active IP Right Grant
- 2010-01-27 US US13/147,242 patent/US9063163B2/en active Active
- 2010-01-27 CN CN2010800049361A patent/CN102292641A/zh active Pending
- 2010-01-27 ES ES10701670.1T patent/ES2525251T3/es active Active
- 2010-01-27 WO PCT/EP2010/050925 patent/WO2010086329A1/en active Application Filing
- 2010-01-27 EP EP10701670.1A patent/EP2391893B1/en active Active
- 2010-01-27 CA CA2750976A patent/CA2750976C/en active Active
- 2010-01-27 MX MX2011007301A patent/MX2011007301A/es active IP Right Grant
- 2010-01-27 NZ NZ593787A patent/NZ593787A/xx unknown
-
2011
- 2011-06-15 IL IL213573A patent/IL213573A/en active IP Right Grant
-
2015
- 2015-05-12 US US14/709,519 patent/US20150240288A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010209804A1 (en) | 2011-07-07 |
| AU2010209804B2 (en) | 2015-07-16 |
| KR20110120882A (ko) | 2011-11-04 |
| EA020194B1 (ru) | 2014-09-30 |
| JP5611983B2 (ja) | 2014-10-22 |
| BRPI1007934B1 (pt) | 2021-08-31 |
| KR101822368B1 (ko) | 2018-01-31 |
| CA2750976C (en) | 2018-10-23 |
| PL2391893T3 (pl) | 2015-03-31 |
| EA201101152A1 (ru) | 2012-03-30 |
| CN102292641A (zh) | 2011-12-21 |
| MX2011007301A (es) | 2011-08-03 |
| JP2012516993A (ja) | 2012-07-26 |
| WO2010086329A1 (en) | 2010-08-05 |
| NZ593787A (en) | 2013-09-27 |
| DK2391893T3 (da) | 2014-12-01 |
| EP2391893A1 (en) | 2011-12-07 |
| EP2391893B1 (en) | 2014-09-03 |
| US9063163B2 (en) | 2015-06-23 |
| CA2750976A1 (en) | 2010-08-05 |
| IL213573A0 (en) | 2011-07-31 |
| IL213573A (en) | 2015-05-31 |
| ES2525251T3 (es) | 2014-12-19 |
| US20120040384A1 (en) | 2012-02-16 |
| US20150240288A1 (en) | 2015-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2018030I1 (el) | Φαρμακοτεχνικη μορφη 514 | |
| BRPI1012004A2 (pt) | "forma farmacêutica" | |
| BR112012012872A2 (pt) | "pirrolindinas de espiroindolinona" | |
| BR112012004593A2 (pt) | "método" | |
| BRPI0911743A2 (pt) | "peptídeo" | |
| BRPI1014856A2 (pt) | "elementos de tração" | |
| BRPI1007934A2 (pt) | "dabigatrana liofilizada" | |
| DK2114993T3 (da) | Vaccine | |
| UY33125A (es) | Diaza-espiro-[5,5]-undecanos | |
| DK2132326T3 (da) | Fremgangsmåder | |
| BRPI1013030A2 (pt) | "aquecedores" | |
| BRPI0914533A2 (pt) | "métodos" | |
| BRPI1013001A2 (pt) | "bioprocessamento" | |
| FR2944062B1 (fr) | Injecteur d'ergols | |
| DE112008003753B8 (de) | Reißverschluss | |
| BRPI0907062A2 (pt) | "hidrociclone" | |
| BRPI1010661A2 (pt) | peptídeo | |
| BRPI1012055A2 (pt) | "piperidinas substituídas" | |
| BRPI1010178A2 (pt) | "válvula" | |
| BRPI1009059A2 (pt) | "peça de vestuário" | |
| MA30860B1 (fr) | Myrtillier denomme "c97-390" | |
| DE202009012799U8 (de) | Bettdecke | |
| FI20080124A0 (fi) | Läheis-Josephson-ilmaisin | |
| BRPI1013017A2 (pt) | "17beta-alquil-17alfa-óxi-estratrienos" | |
| BRPI1014211A2 (pt) | "composição." |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/01/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |